T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Weill Medical College of Cornell University
Beth Israel Deaconess Medical Center
Eli Lilly and Company
M.D. Anderson Cancer Center
University of Maryland, Baltimore
Wake Forest University Health Sciences
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Canadian Cancer Trials Group
National Cancer Institute (NCI)
Astellas Pharma Inc
National Cancer Institute (NCI)
Canadian Cancer Trials Group
Ohio State University Comprehensive Cancer Center
Geisinger Clinic
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Novartis
Thomas Jefferson University
Eastern Cooperative Oncology Group
Spanish Breast Cancer Research Group
Medical College of Wisconsin
Eastern Cooperative Oncology Group
City of Hope Medical Center
Seagen Inc.
Canadian Cancer Trials Group
Sotio Biotech Inc.
University of Colorado, Denver
Adichunchanagiri Institute of Medical Sciences, B G Nagara
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
University of Nebraska
Seagen Inc.
Hoffmann-La Roche
University of Chicago
MedSIR
AstraZeneca
M.D. Anderson Cancer Center
Pfizer
Duke University
Hoffmann-La Roche
University of Texas Southwestern Medical Center
Eastern Cooperative Oncology Group
Spanish Breast Cancer Research Group
Allarity Therapeutics
M.D. Anderson Cancer Center
University of Kansas Medical Center
Medical University of South Carolina